[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
December 2010

Regional Squamous Cell Carcinomas Following Systemic Sorafenib Therapy and Isolated Limb Infusion for Regionally Advanced Metastatic Melanoma of the Limb

Author Affiliations

Author Affiliations: Departments of Dermatology (Ms Raymond and Drs Puri, Selim, and Nelson), Pathology (Drs Puri and Selim), and Surgery, Division of Oncology (Dr Tyler), Duke University Medical Center, Durham, North Carolina.

Arch Dermatol. 2010;146(12):1438-1439. doi:10.1001/archdermatol.2010.367

A 75-year-old white man with a history of nonmelanoma skin cancer was first diagnosed as having a Clark level IV malignant melanoma (Breslow depth, 1.57 mm) of the left lower extremity approximately 19 months prior to presentation. The primary melanoma was treated with therapeutic excision with negative margins, and the patient deferred sentinel node evaluation. Multiple in-transit metastatic melanoma lesions limited to the left leg appeared several months later and were subsequently treated with standard isolated limb infusion (ILI) with melphalan and dactinomycin. Standard ILI delivers 10 to 20 times the typically tolerated systemic chemotherapy dose directly to the affected tourniquet-wrapped extremity through vascular cannulas.

First Page Preview View Large
First page PDF preview
First page PDF preview
×